MDL-28170
Based on 19 publication(s) in Google Scholar
MDL-28170 (Calpain Inhibitor III) is a potent, selective and membrane-permeable cysteine protease inhibitor of calpain that rapidly penetrates the blood-brain barrier following systemic administration. MDL-28170 also block γ-secretase.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 97.0%
- No. CAS: 88191-84-8
- Fòrmula: C22H26N2O4
- Peso molecular:382.45
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Covalent Screening Library
HY-L036
-
Anti-diabetic Compound Library
HY-L040
-
Ubiquitination Compound Library
HY-L050
-
Anti-Blood Cancer Compound Library
HY-L079
-
Protease Inhibitor Library
HY-L147
-
Cysteine Targeted Covalent Library
HY-L153
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) MDL-28170
More- Bioact Mater. 2025 Nov 25:57:646-659. [Abstract]
- J Extracell Vesicles. 2022 Dec;11(12):e12279. [Abstract]
- Cell Death Discov. 2026 Jun 19. [Abstract]
- EMBO J. 2025 Sep 9. [Abstract]
- Am J Chin Med. 2025;53(4):1181-1206. [Abstract]
- J Med Chem. 2024 Oct 10;67(19):17124-17143. [Abstract]
- Emerg Microbes Infect. 2022 Dec;11(1):483-497. [Abstract]
- Acta Neuropathol Commun. 2025 Apr 10;13(1):73. [Abstract]
- Eur J Pharmacol. 2022 Jun 5:924:174940. [Abstract]
- Int Immunopharmacol. 2024 Dec 9:145:113781. [Abstract]
- Chem Biol Interact. 2026 Mar 6:431:112011. [Abstract]
- Sci Rep. 2022 Jul 16;12(1):12197. [Abstract]
- J Med Virol. 2025 May;97(5):e70393. [Abstract]
- BMC Anesthesiol. 2025 Apr 25;25(1):213. [Abstract]
- Neurosci Lett. 2023 Oct 15:815:137494. [Abstract]
- Neurol Res. 2025 May 23:1-13. [Abstract]
- bioRxiv. 2026 May 15.
- bioRxiv. 2026 May 7.
- Heliyon. 2023 Nov 30;9(12):e23076. [Abstract]
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
WB
-
WB
-
IF
-
Bio/Physico-chemical Assay
Actividad biológica
Calpain[1].
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Vero C1008 | EC50 |
0.22 μM
Compound: MDL 28170
|
Determination of antiviral efficacy in high-content imaging assay in Vero E6 cells infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI 0.75 after 24 hrs
Determination of antiviral efficacy in high-content imaging assay in Vero E6 cells infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI 0.75 after 24 hrs
|
10.1101/2020.04.16.044016 |
MDL-28170 significantly and time-dependently improves the recovery of synaptic responses in hippocampal slices following prolonged, moderate hypoxia without hypoxic depolarization[1].
MDL-28170 dose-dependently inhibits brain cysteine proteinase activity (in vitro Ki= 0.01 μM)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MDL-28170 (30 mg/kg, i.p.) reduces the functional and structural deterioration of corpus callosum following fluid percussion injury[3].
MDL-28170 (10 mg/kg, i.p.) significantly improves nerve function parameters in diabetic rats. MDL-28170 (3 and 10 mg/kg, i.p.) improves nociceptive behavior in diabetic rats[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 88191-84-8
-
Appearance Solid
-
Peso molecular 382.45
-
Fòrmula C22H26N2O4
-
Color White to off-white
-
SMILES
O=C(N[C@@H](C(C)C)C(NC(CC1=CC=CC=C1)C=O)=O)OCC2=CC=CC=C2
-
Synonyms
Calpain Inhibitor III
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (19)
-
Journal Impact Factor
-
Most Recent
-
Bioact Mater
Food-derived β-lactoglobulin nanofibrils: An efficacy, safe, and scalable solution to overcome oral insulin delivery challenges. [Abstract]2025 Nov 25:57:646-659. PMID: 41377894
MDL-28170 purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2025 Nov 25:57:646-659. [Abstract]
The calpain inhibitor MDL-28170 (50 μM; 2 h) attenuated nanofibril-induced permeability in Caco-2 cells.
MDL-28170 purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2025 Nov 25:57:646-659. [Abstract]
The calpain inhibitor MDL-28170 (50 μM; 1 h) blocked SBDP150/145 generation without affecting Ca2+ signaling.
-
J Extracell Vesicles
Suppression of PD-L1 release from small extracellular vesicles promotes systemic anti-tumor immunity by targeting ORAI1 calcium channels. [Abstract]2022 Dec;11(12):e12279. PMID: 36482876
MDL-28170 purchased from MedChemExpress. Usage Cited in: J Extracell Vesicles. 2022 Dec;11(12):e12279. [Abstract]
MDL-28170 (Calpain inhibitor III; 10 μM; 48 h) blocks the secretion of sEV PD-L1 in the presence of IFN-γ, in H1299 cells.
MDL-28170 purchased from MedChemExpress. Usage Cited in: J Extracell Vesicles. 2022 Dec;11(12):e12279. [Abstract]
MDL-28170 (Calpain inhibitor III) (10 μM) significantly altered the WT MLPH localization with clusters disappearing and reduced co-localization with actin filaments in H1299 cells. White arrows in the panels pointed to puncta formed by MLPH aggregates. FITC phalloidin staining was used for visualization of the actin cytoskeleton, and blue arrows pointed to actin aggregates in the cell cortex.
MDL-28170 purchased from MedChemExpress. Usage Cited in: J Extracell Vesicles. 2022 Dec;11(12):e12279. [Abstract]
Comparison by NTA of total and PD-L1-EGFP particle size distributions for experiments with or without MDL-28170 (Calpain inhibitor III) (10 µM) treatment in H1299 cells.
-
Cell Death Discov
Thioredoxin system dysregulation and calpain activation drive myocardial disulfidptosis via pathological disulfide bonds remodeling. [Abstract]2026 Jun 19. PMID: 42321161 -
EMBO J
Nuclear paxillin functions as a molecular switch for alternative splicing in neurons during a critical period of brain development. [Abstract]2025 Sep 9. PMID: 40926123 -
Am J Chin Med
Astragaloside IV Improves Pulmonary Vascular Endothelial Dysfunction in Pulmonary Arterial Hypertension by Inhibiting Ferroptosis through Modulation of the Calpain-1/TGF-β/TFRC Pathway. [Abstract]2025;53(4):1181-1206. PMID: 40582717 -
J Med Chem
Peptidomimetic Analogues Act as Effective Inhibitors against SARS-CoV-2 by Blocking the Function of Cathepsin L. [Abstract]2024 Oct 10;67(19):17124-17143. PMID: 39292661 -
Emerg Microbes Infect
Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro. [Abstract]2022 Dec;11(1):483-497. PMID: 34989664 -
Acta Neuropathol Commun
Transient receptor potential vanilloid 4 blockage attenuates pyroptosis in hippocampus of mice following pilocarpine‑induced status epilepticus. [Abstract]2025 Apr 10;13(1):73. PMID: 40205503 -
Eur J Pharmacol
Verdiperstat attenuates acute lung injury by modulating MPO/μ-calpain/β-catenin signaling. [Abstract]2022 Jun 5:924:174940. PMID: 35461824 -
Int Immunopharmacol
Genome-wide screen based on 2DG activated NLRP3 inflammasome reveals the priming signal of TLR2/4 to IKKβ but not IKKα. [Abstract]2024 Dec 9:145:113781. PMID: 39657538 -
Chem Biol Interact
2026 Mar 6:431:112011. PMID: 41796629 -
Sci Rep
Hepatitis C virus NS3/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease. [Abstract]2022 Jul 16;12(1):12197. PMID: 35842458 -
J Med Virol
Influenza A Virus Induces Autophagosome by Inhibiting LTCC/Calpain 2/LC3A Signaling to Promote Viral Replication. [Abstract]2025 May;97(5):e70393. PMID: 40358023 -
BMC Anesthesiol
Etomidate-Induced myoclonus in Sprague‒Dawley rats involves the activation of neocortical Calpain-2 and its decrement on KCC2 protein. [Abstract]2025 Apr 25;25(1):213. PMID: 40281446 -
Neurosci Lett
Downregulation of NHE1 expression attenuates apoptosis of primary hippocampal neurons of an epilepsy model through the calpain-1 pathway. [Abstract]2023 Oct 15:815:137494. PMID: 37748674 -
Neurol Res
EphB receptors modulate neuropathic pain via Ca2+/calpain/autophagy in spinal cord of mice. [Abstract]2025 May 23:1-13. PMID: 40407305 -
-
-
Heliyon
Baicalin attenuates pulmonary vascular remodeling by inhibiting calpain-1 mediated endothelial-to-mesenchymal transition. [Abstract]2023 Nov 30;9(12):e23076. PMID: 38144352
Solvente y solubilidad
DMSO : 30 mg/mL (78.44 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.25 mg/mL (5.88 mM); Clear solution
This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Chen ZF, et al. Neuronal recovery after moderate hypoxia is improved by the calpain inhibitor MDL28170. Brain Res. 1997 Sep 19;769(1):188-92. [Content Brief]
[2]. Li PA, et al. Postischemic treatment with calpain inhibitor MDL 28170 ameliorates brain damage in a gerbil model of global ischemia. Neurosci Lett. 1998 May 8;247(1):17-20. [Content Brief]
[3]. Ai J, et al. Calpain inhibitor MDL-28170 reduces the functional and structural deterioration of corpus callosum following fluid percussion injury. J Neurotrauma. 2007 Jun;24(6):960-78. [Content Brief]
[4]. De Strooper B, et al. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999 Apr 8;398(6727):518-22. [Content Brief]
[5]. Kharatmal SB, et al. Calpain inhibitor, MDL 28170 confer electrophysiological, nociceptive and biochemical improvement in diabetic neuropathy. Neuropharmacology. 2015 Oct;97:113-21. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6147 mL | 13.0736 mL | 26.1472 mL | 65.3680 mL |
| 5 mM | 0.5229 mL | 2.6147 mL | 5.2294 mL | 13.0736 mL | |
| 10 mM | 0.2615 mL | 1.3074 mL | 2.6147 mL | 6.5368 mL | |
| 15 mM | 0.1743 mL | 0.8716 mL | 1.7431 mL | 4.3579 mL | |
| 20 mM | 0.1307 mL | 0.6537 mL | 1.3074 mL | 3.2684 mL | |
| 25 mM | 0.1046 mL | 0.5229 mL | 1.0459 mL | 2.6147 mL | |
| 30 mM | 0.0872 mL | 0.4358 mL | 0.8716 mL | 2.1789 mL | |
| 40 mM | 0.0654 mL | 0.3268 mL | 0.6537 mL | 1.6342 mL | |
| 50 mM | 0.0523 mL | 0.2615 mL | 0.5229 mL | 1.3074 mL | |
| 60 mM | 0.0436 mL | 0.2179 mL | 0.4358 mL | 1.0895 mL |
MDL-28170 Related Classifications
HY-18236 Related Classifications
Powered by Bioz